Digestive Diseases and Sciences

, Volume 51, Issue 3, pp 600–602 | Cite as

De Novo Hepatocellular Carcinomain a Patient with Chronic Hepatitis C 5 Years After Sustained Virologic Response to Interferon/Ribavirin Therapy

  • Kevin S. Sieja
  • Gregory T. Everson

Key Words

chronic hepatitis C interferon sustained responder hepatocellular carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36:S74–S83, 2002CrossRefPubMedGoogle Scholar
  2. 2.
    Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Hepatology 26:34S–38S, 1997CrossRefPubMedGoogle Scholar
  3. 3.
    Ray RB, Meyer K, Ray R: Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226:176–182, 1996CrossRefPubMedGoogle Scholar
  4. 4.
    Sherlock S: Viruses and hepatocellular carcinoma. Gut 35:828–832, 1994PubMedGoogle Scholar
  5. 5.
    Mas VR, Maluf DG, Stravitz R, et al.: Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: Genes involved in tumor progression. Liver Transpl 10:607–620, 2004CrossRefPubMedGoogle Scholar
  6. 6.
    Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1055, 1995CrossRefPubMedGoogle Scholar
  7. 7.
    Camma C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 34:593–602, 2001PubMedGoogle Scholar
  8. 8.
    Sugiura N, Sakai Y, Ebara M, et al.: Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: Clinical study of 26 cases. J Gastroenterol Hepatol 11:535–539, 1996PubMedGoogle Scholar
  9. 9.
    Sugo H, Kitayama N, Iwata T: Development of hepatocellular carcinoma in a patient with chronic hepatitis C after a complete response to interferon therapy. Acta Hepat Jpn 41:195–198, 2000Google Scholar
  10. 10.
    Yamada M, Ichikawa M, Matsubara A, Ishiguro Y, Yamada M, Yokoi S: Development of small hepatocellular carcinoma 80 months after clearance of hepatitis C with interferon therapy. Eur J Gastroenterol Hepatol 12:1029–1032, 2000PubMedGoogle Scholar
  11. 11.
    Makiyama A, Itoh Y, Kasahara A, et al.: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 101:1616–1622, 2004CrossRefPubMedGoogle Scholar
  12. 12.
    Yoshida H, Shiratori Y, Moriyama M, et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174–181, 1999PubMedGoogle Scholar
  13. 13.
    Kato Y, Hamasaki K, Aritomi T, Nakao K, Nakata K, Eguchi K: Most of the patients with cirrhosis in Japan die from hepatocellular carcinoma. Oncol Rep 6:1273–1276, 1999PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyUniversity of Colorado Health Sciences CenterDenverUSA
  2. 2.Division of Gastroenterology and HepatologyUniversity of Colorado Health Sciences CenterDenver

Personalised recommendations